BackInVivo Therapeutics Holdings Overview

InVivo Therapeutics Holdings Current Cash

InVivo Therapeutics Holdings's current cash is $8.6M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$8.58M
19.02% YoYΔ $-2.02M vs prior year quarter

Peer average

Loading

InVivo Therapeutics Holdings Current Cash History

Loading

InVivo Therapeutics Holdings vs. peers: Current Cash Comparison

Loading

InVivo Therapeutics Holdings Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

InVivo Therapeutics Holdings (NVIV) FAQ

InVivo Therapeutics Holdings posts a current cash of $8.6M as of September 2023. That compares with $11M in the prior-year period — down 19.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, InVivo Therapeutics Holdings's current cash was $11M. The latest reading is $8.6M — a 19.0% year-over-year decrease (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of InVivo Therapeutics Holdings's financial statement story. At $8.6M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for NVIV's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; InVivo Therapeutics Holdings's other metric pages and overview cover the third.

Judging InVivo Therapeutics Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in current cash easier to interpret. Start with $8.6M here, then scan peer and history charts to see if the gap is persistent.